Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Urinary Bladder Neoplasms HELP
Based on 16,342 articles published since 2009
|||| 12 

These are the 16342 published articles about Urinary Bladder Neoplasms that originated from Worldwide during 2009-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer. 2019

Merseburger, Axel S / Apolo, Andrea B / Chowdhury, Simon / Hahn, Noah M / Galsky, Matthew D / Milowsky, Matthew I / Petrylak, Daniel / Powles, Tom / Quinn, David I / Rosenberg, Jonathan E / Siefker-Radtke, Arlene / Sonpavde, Guru / Sternberg, Cora N. ·Department of Urology, Campus Lübeck, University Hospital Schleswig-Holstein, Lübeck, Germany. · Center for Cancer Research, National Cancer Institute, NIH Maryland, Bethesda, USA. · Guy's and St, Thomas' Hospital, Great Maze Pond, London, UK. · Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA. · Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA. · Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA. · Yale Cancer Center, New Haven, CT, USA. · Barts Cancer Institute, London, USA. · Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. · Memorial Sloan Kettering Cancer Center, New York, USA. · Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. · Department of Medical Oncology, Bladder Cancer Center, Dana Farber Cancer Institute, Boston, MA, USA. · Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy. cnsternberg@corasternberg.com. ·World J Urol · Pubmed #30238401.

ABSTRACT: The SIU (Société Internationale d'Urologie)-ICUD (International Consultation on Urologic Diseases) working group on systemic therapy for metastatic bladder cancer has summarized the most recent findings on the aforementioned topic and came to conclusions and recommendations according to the evidence published. In Europe and the United States, treatment for metastatic UC has changed a great deal recently, mainly involving a move from chemotherapy to immune checkpoint blockers. This is particularly true in platinum-refractory disease, where supportive randomized data exist. Five checkpoint blockers have been approved in this setting by the FDA: avelumab, atezolizumab, durvalumab, nivolumab, and pembrolizumab. Nivolumab, pembrolizumab, and atezolizumab have been approved in Europe.

2 Guideline [French ccAFU guidelines - Update 2018-2020: Bladder cancer]. 2018

Rouprêt, M / Neuzillet, Y / Pignot, G / Compérat, E / Audenet, F / Houédé, N / Larré, S / Masson-Lecomte, A / Colin, P / Brunelle, S / Xylinas, E / Roumiguié, M / Méjean, A. ·Comité de cancérologie de l'Association française d'urologie, groupe vessie, maison de l'urologie, 11, rue Viète, 75017 Paris, France; Sorbonne université, GRC no5, ONCOTYPE-URO, hôpital Pitié-Salpêtrière, AP-HP, 75013 Paris, France. Electronic address: morgan.roupret@aphp.fr. · Comité de cancérologie de l'Association française d'urologie, groupe vessie, maison de l'urologie, 11, rue Viète, 75017 Paris, France; Service d'urologie, hôpital Foch, université de Versailles-Saint-Quentin-en-Yvelines, 92150 Suresnes, France. · Comité de cancérologie de l'Association française d'urologie, groupe vessie, maison de l'urologie, 11, rue Viète, 75017 Paris, France; Service de chirurgie oncologique 2, institut Paoli-Calmettes, 13008 Marseille, France. · Comité de cancérologie de l'Association française d'urologie, groupe vessie, maison de l'urologie, 11, rue Viète, 75017 Paris, France; Service d'anatomie pathologique, hôpital Tenon, HUEP, Sorbonne université, GRC no5, ONCOTYPE-URO, 75020 Paris, France. · Comité de cancérologie de l'Association française d'urologie, groupe vessie, maison de l'urologie, 11, rue Viète, 75017 Paris, France; Service d'urologie, hôpital européen Georges-Pompidou, université Paris Descartes, AP-HP, 75015 Paris, France. · Comité de cancérologie de l'Association française d'urologie, groupe vessie, maison de l'urologie, 11, rue Viète, 75017 Paris, France; Département d'oncologie médicale, CHU Caremaux, Montpellier université, 30000 Nîmes, France. · Comité de cancérologie de l'Association française d'urologie, groupe vessie, maison de l'urologie, 11, rue Viète, 75017 Paris, France; Service d'urologie, CHU de Reims, Reims, 51100 France. · Comité de cancérologie de l'Association française d'urologie, groupe vessie, maison de l'urologie, 11, rue Viète, 75017 Paris, France; Service d'urologie, hôpital Saint-Louis, université Paris-Diderot, 75010 Paris, France. · Comité de cancérologie de l'Association française d'urologie, groupe vessie, maison de l'urologie, 11, rue Viète, 75017 Paris, France; Service d'urologie, hôpital privé de la Louvière, 59800 Lille, France. · Comité de cancérologie de l'Association française d'urologie, groupe vessie, maison de l'urologie, 11, rue Viète, 75017 Paris, France; Service de radiologie, institut Paoli-Calmettes, 13008 Marseille, France. · Comité de cancérologie de l'Association française d'urologie, groupe vessie, maison de l'urologie, 11, rue Viète, 75017 Paris, France; Service d'urologie de l'hôpital Bichat-Claude-Bernard, université Paris-Descartes, Assistance publique-Hôpitaux de Paris, 75018 Paris, France. · Comité de cancérologie de l'Association française d'urologie, groupe vessie, maison de l'urologie, 11, rue Viète, 75017 Paris, France; Département d'urologie, CHU Rangueil, Toulouse, 31000 France. ·Prog Urol · Pubmed #30366708.

ABSTRACT: OBJECTIVE: To propose updated French guidelines for non-muscle invasive (NMIBC) and muscle-invasive (MIBC) bladder cancers. METHODS: A Medline search was achieved between 2015 and 2018, as regards diagnosis, options of treatment and follow-up of bladder cancer, to evaluate different references with levels of evidence. RESULTS: Diagnosis of NMIBC (Ta, T1, CIS) is based on a complete deep resection of the tumor. The use of fluorescence and a second-look indication are essential to improve initial diagnosis. Risks of both recurrence and progression can be estimated using the EORTC score. A stratification of patients into low, intermediate and high risk groups is pivotal for recommending adjuvant treatment: instillation of chemotherapy (immediate post-operative, standard schedule) or intravesical BCG (standard schedule and maintenance). Cystectomy is recommended in BCG-refractory patients. Extension evaluation of MIBC is based on contrast-enhanced pelvic-abdominal and thoracic CT-scan. Multiparametric MRI can be an alternative. Cystectomy associated with extended lymph nodes dissection is considered the gold standard for non-metastatic MIBC. It should be preceded by cisplatin-based neoadjuvant chemotherapy in eligible patients. An orthotopic bladder substitution should be proposed to both male and female patients with no contraindication and in cases of negative frozen urethral samples; otherwise transileal ureterostomy is recommended as urinary diversion. All patients should be included in an Early Recovery After Surgery (ERAS) protocol. For metastatic MIBC, first-line chemotherapy using platin is recommended (GC or MVAC), when performans status (PS<1) and renal function (creatinine clearance>60 mL/min) allow it (only in 50% of cases). In second line treatment, immunotherapy with pembrolizumab demonstrated a significant improvement in overall survival. CONCLUSION: These updated French guidelines will contribute to increase the level of urological care for the diagnosis and treatment for NMIBC and MIBC.

3 Guideline Indication for a Single Postoperative Instillation of Chemotherapy in Non-muscle-invasive Bladder Cancer: What Factors Should Be Considered? 2018

Babjuk, Marko / Burger, Maximilian / Compérat, Eva M / Gontero, Paolo / Mostafid, Hugh A / Palou, Joan / van Rhijn, Bas W G / Rouprêt, Morgan / Shariat, Shahrokh F / Sylvester, Richard / Zigeuner, Richard / Capoun, Otakar / Cohen, Daniel / Dominguez-Escrig, José L / Hernández, Virginia / Peyronnet, Benoit / Seisen, Thomas / Soukup, Viktor / Anonymous1751121. ·Department of Urology, Hospital Motol, Second Faculty of Medicine, Charles University, Praha, Czech Republic; Medical University of Vienna, Vienna General Hospital, Vienna, Austria. Electronic address: marek.babjuk@fnmotol.cz. · Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany. · Department of Pathology, Hôpital Tenon, AP-HP, Sorbonne University, Paris, France. · Department of Urology, San Giovanni Battista Hospital, Città della Salute e della Scienza, University of Turin, Turin, Italy. · Department of Urology, Royal Surrey County Hospital, Guildford, UK. · Department of Urology, Fundació Puigvert, Universidad Autónoma de Barcelona, Barcelona, Spain. · Department of Urology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. · Department of Urology, Hôpital La Pitié-Salpétrière, AP-HP, Sorbonne University, Paris, France. · Department of Urology, Hospital Motol, Second Faculty of Medicine, Charles University, Praha, Czech Republic; Medical University of Vienna, Vienna General Hospital, Vienna, Austria; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Urology, Weill Cornell Medical College, New York, NY, USA. · European Association of Urology Guidelines Office, Brussels, Belgium. · Department of Urology, Medical University of Graz, Graz, Austria. · Department of Urology, General University Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic. · Department of Surgery and Cancer, Imperial College London, London, UK; Department of Urology, Lister Hospital, East and North Hertfordshire NHS Trust, Stevenage, UK. · Servicio de Urología, Fundación Instituto Valenciano de Oncología, Valencia, Spain. · Department of Urology, Hospital Universitario Fundación Alcorcón, Madrid, Spain. · Service d'Urologie, CHU de Rennes, Rennes, France. ·Eur Urol Focus · Pubmed #30061076.

ABSTRACT: An early single instillation of intravesical chemotherapy (SICI) used immediately after transurethral resection of the bladder (TURB) can significantly reduce the recurrence rate in selected patients with non-muscle-invasive bladder cancer (NMIBC). SICI should be used in patients with low-risk and with selected intermediate-risk tumours, in particular for multiple primary small papillary tumours, single primary papillary tumours >3cm, and single recurrent papillary tumours recurring >1yr after the previous resection. The available data do not support any recommendation to reduce the role of SICI in patients after fluorescence cystoscopy-guided TURB or en bloc TURB. SICI can even provide some benefit in patients with intermediate-risk tumours subsequently treated with further instillations. During instillation, contraindications should be taken into account and safety measures should be applied. PATIENT SUMMARY: An early single instillation of intravesical chemotherapy immediately after transurethral resection of the bladder can significantly reduce the recurrence rate in selected patients with non-muscle-invasive bladder cancer. It should be used in patients with low-risk and selected intermediate-risk tumours.

4 Guideline 9 - Tossicità Da Trattamento Radioterapico E Da Terapia Sistemica Per Neoplasia Vescicale. 2018

Anonymous4730951. · ·Tumori · Pubmed #29893178.

ABSTRACT: -- No abstract --

5 Guideline 7 - Terapia Nella Malattia In Progressione E Metastatica. 2018

Anonymous4700951. · ·Tumori · Pubmed #29893176.

ABSTRACT: -- No abstract --

6 Guideline Linee Guida AIRO-AIRB 2018: Neoplasie della Vescica. 2018

Anonymous4660951. · ·Tumori · Pubmed #29893173.

ABSTRACT: -- No abstract --

7 Guideline 10 - Nuove Tecnologie in Radioterapia E Prospettive Future. 2018

Anonymous4670951. · ·Tumori · Pubmed #29893172.

ABSTRACT: -- No abstract --

8 Guideline 6 - Terapia Trimodale Nel Trattamento Conservativo Della Neoplasia Vescicale. 2018

Anonymous4650951. · ·Tumori · Pubmed #29893171.

ABSTRACT: -- No abstract --

9 Guideline 5 - Trattamento Chirurgico Della Malattia Muscolo-Invasiva E Localmente Avanzata (MIBC). 2018

Anonymous4640951. · ·Tumori · Pubmed #29893170.

ABSTRACT: -- No abstract --

10 Guideline 4 - Trattamento Chirurgico Della Malattia Non Muscolo-Invasiva (NMIBC). 2018

Anonymous4620951. · ·Tumori · Pubmed #29893169.

ABSTRACT: -- No abstract --

11 Guideline 3 - Diagnosi E Stadiazione. 2018

Anonymous4630951. · ·Tumori · Pubmed #29893168.

ABSTRACT: -- No abstract --

12 Guideline ACR Appropriateness Criteria 2018

Anonymous1231079 / van der Pol, Christian B / Sahni, V Anik / Eberhardt, Steven C / Oto, Aytekin / Akin, Oguz / Alexander, Lauren F / Allen, Brian C / Coakley, Fergus V / Froemming, Adam T / Fulgham, Pat F / Hosseinzadeh, Keyanoosh / Maranchie, Jodi K / Mody, Rekha N / Schieda, Nicola / Schuster, David M / Venkatesan, Aradhana M / Wang, Carolyn L / Lockhart, Mark E. ·Research Author, Brigham & Women's Hospital, Boston, Massachusetts. · Principal Author, Brigham & Women's Hospital, Boston, Massachusetts. Electronic address: vassahni@hotmail.com. · Panel Chair, University of New Mexico, Albuquerque, New Mexico. · Panel Vice Chair, University of Chicago, Chicago, Illinois. · Memorial Sloan Kettering Cancer Center, New York, New York. · Emory University Hospital, Atlanta, Georgia. · Duke University Medical Center, Durham, North Carolina. · Oregon Health & Science University, Portland, Oregon. · Mayo Clinic, Rochester, Minnesota. · Urology Clinics of North Texas, Dallas, Texas; American Urological Association. · Veterans Administration, Durham, North Carolina. · UPMC, Pittsburgh, Pennsylvania; American Urological Association. · Cleveland Clinic, Cleveland, Ohio. · Ottawa Hospital Research Institute and the Department of Radiology, The University of Ottawa, Ottawa, Ontario, Canada. · University of Texas MD Anderson Cancer Center, Houston, Texas. · University of Washington, Seattle Cancer Care Alliance, Seattle, Washington. · Specialty Chair, University of Alabama at Birmingham, Birmingham, Alabama. ·J Am Coll Radiol · Pubmed #29724418.

ABSTRACT: Muscle-invasive bladder cancer (MIBC) has a tendency toward urothelial multifocality and is at risk for local and distant spread, most commonly to the lymph nodes, bone, lung, liver, and peritoneum. Pretreatment staging of MIBC should include imaging of the urothelial upper tract for synchronous lesions; imaging of the chest, abdomen, and pelvis for metastases; and MRI pelvis for local staging. CT abdomen and pelvis without and with contrast (CT urogram) is recommended to assess the urothelium and abdominopelvic organs. Pelvic MRI can improve local bladder staging accuracy. Chest imaging is also recommended with chest radiograph usually being adequate. FDG-PET/CT may be appropriate to identify nodal and metastatic disease. Chest CT may be useful in high-risk patients and those with findings on chest radiograph. Nonurogram CT and MRI of the abdomen and pelvis are usually not appropriate, and neither is radiographic intravenous urography, Tc-99m whole body bone scan, nor bladder ultrasound for pretreatment staging of MIBC. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.

13 Guideline Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. 2017

Spiess, Philippe E / Agarwal, Neeraj / Bangs, Rick / Boorjian, Stephen A / Buyyounouski, Mark K / Clark, Peter E / Downs, Tracy M / Efstathiou, Jason A / Flaig, Thomas W / Friedlander, Terence / Greenberg, Richard E / Guru, Khurshid A / Hahn, Noah / Herr, Harry W / Hoimes, Christopher / Inman, Brant A / Jimbo, Masahito / Kader, A Karim / Lele, Subodh M / Meeks, Joshua J / Michalski, Jeff / Montgomery, Jeffrey S / Pagliaro, Lance C / Pal, Sumanta K / Patterson, Anthony / Plimack, Elizabeth R / Pohar, Kamal S / Porter, Michael P / Preston, Mark A / Sexton, Wade J / Siefker-Radtke, Arlene O / Sonpavde, Guru / Tward, Jonathan / Wile, Geoffrey / Dwyer, Mary A / Gurski, Lisa A. · ·J Natl Compr Canc Netw · Pubmed #28982750.

ABSTRACT: This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on systemic therapy for muscle-invasive urothelial bladder cancer, as substantial revisions were made in the 2017 updates, such as new recommendations for nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab. The complete version of the NCCN Guidelines for Bladder Cancer addresses additional aspects of the management of bladder cancer, including non-muscle-invasive urothelial bladder cancer and nonurothelial histologies, as well as staging, evaluation, and follow-up.

14 Guideline Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary. 2017

Chang, Sam S / Bochner, Bernard H / Chou, Roger / Dreicer, Robert / Kamat, Ashish M / Lerner, Seth P / Lotan, Yair / Meeks, Joshua J / Michalski, Jeff M / Morgan, Todd M / Quale, Diane Z / Rosenberg, Jonathan E / Zietman, Anthony L / Holzbeierlein, Jeffrey M. ·Vanderbilt University Medical Center, Nashville, TN; Memorial Sloan Kettering Cancer Center, New York, NY; Oregon Health & Science University School of Medicine, Portland, OR; University of Virginia, Charlottesville, VA; MD Anderson Cancer Center; Baylor College of Medicine, Houston; UT Southwestern, Dallas, TX; Northwestern University, Chicago, IL; Washington University School of Medicine, Saint Louis, MO; University of Michigan, Ann Arbor, MI; Bladder Cancer Advocacy Network, Bethesda, MD; Massachusetts General Hospital, Salem, MA; and Kansas University Medical Center, Kansas City, KS. ·J Oncol Pract · Pubmed #28796558.

ABSTRACT: -- No abstract --

15 Guideline Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline. 2017

Chang, Sam S / Bochner, Bernard H / Chou, Roger / Dreicer, Robert / Kamat, Ashish M / Lerner, Seth P / Lotan, Yair / Meeks, Joshua J / Michalski, Jeff M / Morgan, Todd M / Quale, Diane Z / Rosenberg, Jonathan E / Zietman, Anthony L / Holzbeierlein, Jeffrey M. ·American Urological Association Education and Research, Inc., Linthicum, Maryland; American Society of Clinical Oncology, Alexandria, Virginia; American Society for Radiation Oncology, Arlington, Virginia; Society of Urologic Oncology, Inc., Schaumburg, Illinois. ·J Urol · Pubmed #28456635.

ABSTRACT: PURPOSE: This multidisciplinary, evidence-based guideline for clinically non-metastatic muscle-invasive bladder cancer focuses on the evaluation, treatment and surveillance of muscle-invasive bladder cancer guided toward curative intent. MATERIALS AND METHODS: A systematic review utilizing research from the Agency for Healthcare Research and Quality as well as additional supplementation by the authors and consultant methodologists was used to develop the guideline. Evidence-based statements were based on body of evidence strengths Grade A, B or C and were designated as Strong, Moderate and Conditional Recommendations with additional statements presented in the form of Clinical Principles or Expert Opinions. RESULTS: For the first time for any type of malignancy, the American Urological Association, American Society of Clinical Oncology, American Society for Radiation Oncology and Society of Urologic Oncology have formulated an evidence-based guideline based on a risk-stratified clinical framework for the management of muscle-invasive urothelial bladder cancer. This document is designed to be used in conjunction with the associated treatment algorithm. CONCLUSIONS: The intensity and scope of care for muscle-invasive bladder cancer should focus on the patient, disease and treatment response characteristics. This guideline attempts to improve a clinician's ability to evaluate and treat each patient, but higher quality evidence in future trials will be essential to improve level of care for these patients.

16 Guideline GEC-ESTRO/ACROP recommendations for performing bladder-sparing treatment with brachytherapy for muscle-invasive bladder carcinoma. 2017

Pieters, Bradley R / van der Steen-Banasik, Elzbieta / Smits, Geert A / De Brabandere, Marisol / Bossi, Alberto / Van Limbergen, Erik. ·Academic Medical Center/University of Amsterdam, The Netherlands. Electronic address: b.r.pieters@amc.uva.nl. · Radiotherapy Group, Arnhem, The Netherlands. · Rijnstate Hospital, Arnhem, The Netherlands. · University Hospital Gasthuisberg, Leuven, Belgium. · Gustave Roussy Cancer Campus, Villejuif, France. ·Radiother Oncol · Pubmed #28049550.

ABSTRACT: The standard treatment for muscle-invasive bladder cancer (MIBC) is a radical cystectomy with pelvic lymph node dissection with or without neoadjuvant chemotherapy. In selected cases a bladder sparing approach is possible, for example a limited surgical excision combined with external beam radiotherapy and brachytherapy. To perform brachytherapy flexible catheters have to be implanted in the bladder wall. The implantation is done either by the open retropubic approach or the endoscopic surgical approach. The largest experience for brachytherapy is with low-dose rate and pulsed-dose rate, although some short-term experience with high-dose rate is also reported. The main advantage for this technique is the conservation of bladder function, with comparable local control rates as for cystectomy series in selected cases. The GEC-ESTRO/ACROP (Groupe Européen de Curiethérapie-European Society for Radiotherapy and Oncology / Advisory Committee on Radiation Oncology Practice) recommendations to perform bladder implantations and brachytherapy as a treatment option for MIBC are described.

17 Guideline Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. 2017

Alfred Witjes, J / Lebret, Thierry / Compérat, Eva M / Cowan, Nigel C / De Santis, Maria / Bruins, Harman Maxim / Hernández, Virginia / Espinós, Estefania Linares / Dunn, James / Rouanne, Mathieu / Neuzillet, Yann / Veskimäe, Erik / van der Heijden, Antoine G / Gakis, Georgios / Ribal, Maria J. ·Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. Electronic address: Fred.Witjes@radboudumc.nl. · Hôpital Foch, Department of Urology, University of Versailles-Saint-Quentin-en-Yvelines, Suresnes, France. · Department of Pathology, Hôpital La Pitié Salpetrière, UPMC, Paris, France. · Radiology Department, Queen Alexandra Hospital, Portsmouth, UK. · University of Warwick, Cancer Research Unit, Coventry, UK; Queen Elizabeth Hospital, Birmingham, UK. · Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. · Department of Urology, Hospital Universitario Fundación Alcorcón, Madrid, Spain. · Department of Urology, Hospital Universitario Infanta Sofia, Madrid, Spain. · Department of Urology, Derriford Hospital, Plymouth, UK. · Department of Urology, Tampere University Hospital, Tampere, Finland. · Department of Urology, Eberhard-Karls University, Tübingen, Germany. · Department of Urology, Hospital Clinic, University of Barcelona, Barcelona, Spain. ·Eur Urol · Pubmed #27375033.

ABSTRACT: CONTEXT: Invasive bladder cancer is a frequently occurring disease with a high mortality rate despite optimal treatment. The European Association of Urology (EAU) Muscle-invasive and Metastatic Bladder Cancer (MIBC) Guidelines are updated yearly and provides information to optimise diagnosis, treatment, and follow-up of this patient population. OBJECTIVE: To provide a summary of the EAU guidelines for physicians and patients confronted with muscle-invasive and metastatic bladder cancer. EVIDENCE ACQUISITION: An international multidisciplinary panel of bladder cancer experts reviewed and discussed the results of a comprehensive literature search of several databases covering all sections of the guidelines. The panel defined levels of evidence and grades of recommendation according to an established classification system. EVIDENCE SYNTHESIS: Epidemiology and aetiology of bladder cancer are discussed. The proper diagnostic pathway, including demands for pathology and imaging, is outlined. Several treatment options, including bladder-sparing treatments and combinations of treatment modalities (different forms of surgery, radiation therapy, and chemotherapy) are described. Sequencing of these modalities is discussed. Potential indications and contraindications, such as comorbidity, are related to treatment choice. There is a new paragraph on organ-sparing approaches, both in men and in women, and on minimal invasive surgery. Recommendations for chemotherapy in fit and unfit patients are provided including second-line options. Finally, a follow-up schedule is provided. CONCLUSIONS: The current summary of the EAU Muscle-invasive and Metastatic Bladder Cancer Guidelines provides an up-to-date overview of the available literature and evidence dealing with diagnosis, treatment, and follow-up of patients with metastatic and muscle-invasive bladder cancer. PATIENT SUMMARY: Bladder cancer is an important disease with a high mortality rate. These updated guidelines help clinicians refine the diagnosis and select the appropriate therapy and follow-up for patients with metastatic and muscle-invasive bladder cancer.

18 Guideline [CCAFU french national guidelines 2016-2018 on bladder cancer]. 2016

Rouprêt, M / Neuzillet, Y / Masson-Lecomte, A / Colin, P / Compérat, E / Dubosq, F / Houédé, N / Larré, S / Pignot, G / Puech, P / Roumiguié, M / Xylinas, E / Méjean, A. ·Comité de cancérologie de l'Association française d'urologie, groupe vessie, maison de l'urologie, 11, rue Viète, 75017 Paris, France. ·Prog Urol · Pubmed #27846935.

ABSTRACT: OBJECTIVE: The purpose of the guidelines national committee CCAFU on bladder cancer was to propose updated french guidelines for non-muscle invasive (NMIBC) and invasive (MIBC) bladder cancers. METHODS: A Medline search was achieved between 2013 and 2016, as regards diagnosis, options of treatment and follow-up of bladder cancer, to evaluate different references with levels of evidence. RESULTS: Diagnosis of NMIBC (Ta, T1, CIS) is based on a complete deep resection of the tumour. The use of fluorescence and a second-look indication are essential to improve initial diagnosis. Risks of both recurrence and progression can be estimated using the EORTC score. A stratification of patients into low, intermediate and high risk groups is pivotal for recommending adjuvant treatment : instillation of chemotherapy (immediate post-operative, standard schedule) or intravesical BCG (standard schedule and maintenance). Cystectomy is recommended in BCG-refractory patients. Extension evaluation of MIBC is based on pelvic-abdominal and thoracic CT-scan; MRI and FDG-PET remain optional. Cystectomy associated with extensive pelvic lymph nodes resection is considered the gold standard for non metastatic MIBC. An orthotopic bladder substitution should be proposed to both male and female patients lacking any contraindications and in cases of negative frozen urethral samples. The interest of neoadjuvant chemotherapy is well known for all MIBC, wathever the stage. Thus, neoadjuvant chemotherapy is recommended for all eligible patients according PS (PS <2) and renal function (clearance > 60ml/mn). As regards metastatic MIBC, first-line chemotherapy using platin is recommended (GC or MVAC). In second line treatment, only chemotherapy using vinflunine has been validated to date, even if results of immunotherapy clinical trials are encouraging. CONCLUSION: These updated french guidelines will contribute to increase the level of urological care for the diagnosis and treatment for NMIBC and MIBC. © 2016 Elsevier Masson SAS. All rights reserved.

19 Guideline [Radiotherapy of bladder cancer]. 2016

Riou, O / Chauvet, B / Lagrange, J-L / Martin, P / Llacer Moscardo, C / Charissoux, M / Lauche, O / Aillères, N / Fenoglietto, P / Azria, D. ·Département de cancérologie radiothérapie, ICM-Val d'Aurelle, rue de la Croix-Verte, 34298 Montpellier, France. Electronic address: olivier.riou@icm.unicancer.fr. · Service de radiothérapie, institut Sainte-Catherine, BP 846, 84082 Avignon cedex 2, France. · Université Paris Est-Créteil, avenue du Général-de-Gaulle, 94010 Créteil cedex, France; Service de radiothérapie, hôpital Henri-Mondor, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil cedex, France. · Service de radiothérapie, centre Joliot-Curie, route de Desvres, 62280 Saint-Martin-Boulogne, France. · Département de cancérologie radiothérapie, ICM-Val d'Aurelle, rue de la Croix-Verte, 34298 Montpellier, France. ·Cancer Radiother · Pubmed #27521030.

ABSTRACT: Surgery (radical cystectomy) is the standard treatment of muscle-invasive bladder cancer. Radiochemotherapy has risen as an alternative treatment option to surgery as part as organ-sparing combined modality treatment or for patients unfit for surgery. Radiochemotherapy achieves 5-year bladder intact survival of 40 to 65% and 5-year overall survival of 40 to 50% with excellent quality of life. This article introduces the French recommendations for radiotherapy of bladder cancer: indications, exams, technique, dosimetry, delivery and image guidance.

20 Guideline Singapore Cancer Network (SCAN) Guidelines for Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer. 2015

Anonymous6720854. · ·Ann Acad Med Singapore · Pubmed #26763059.

ABSTRACT: INTRODUCTION: The SCAN genitourinary cancer workgroup aimed to develop Singapore Cancer Network (SCAN) clinical practice guidelines for neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer (MIBC). MATERIALS AND METHODS: The workgroup utilised a modified ADAPTE process to calibrate high quality international evidence-based clinical practice guidelines to our local setting. RESULTS: Three international guidelines were evaluated- those developed by the National Comprehensive Cancer Network (2014), the European Society of Medical Oncology (2011) and the European Association of Urology (2013). Recommendations on the use of neoadjuvant and adjuvant chemotherapy in MIBC were developed. CONCLUSION: These adapted guidelines form the SCAN Guidelines 2015 for neoadjuvant and adjuvant chemotherapy in MIBC.

21 Guideline European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. 2015

Rouprêt, Morgan / Babjuk, Marko / Compérat, Eva / Zigeuner, Richard / Sylvester, Richard J / Burger, Maximilian / Cowan, Nigel C / Böhle, Andreas / Van Rhijn, Bas W G / Kaasinen, Eero / Palou, Joan / Shariat, Shahrokh F. ·Department of Urology, Hospital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, University Pierre et Marie Curie, Institut Universitaire de Cancérologie, Paris, France. Electronic address: morgan.roupret@aphp.fr. · Department of Urology, Hospital Motol and 2nd Faculty of Medicine, Charles University, Prague, Czech Republic. · Department of Pathology, Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, University Pierre et Marie Curie, Institut Universitaire de Cancérologie, Paris, France. · Department of Urology, Medizinische Universität Graz, Graz, Austria. · EAU Guidelines Office Board, European Association of Urology, The Netherlands. · Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany. · Department of Radiology, Queen Alexandra Hospital, Portsmouth, UK. · Helios Agnes Karll Krankenhaus, Schwartau, Germany. · Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. · Department of Surgery, Hyvinkää Hospital, Hyvinkää, Finland. · Department of Urology, Universitat Autònoma de Barcelona-Fundació Puigvert, Barcelona, Spain. · Department of Urology, Comprehensive Cancer Centre, Medical University of Vienna, Vienna General Hospital, Vienna, Austria; Department of Urology, Weill Medical College of Cornell University, New York, NY, USA; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. ·Eur Urol · Pubmed #26188393.

ABSTRACT: CONTEXT: The European Association of Urology (EAU) guidelines panel on upper urinary tract urothelial cell carcinoma (UTUC) has prepared updated guidelines to aid clinicians in the current evidence-based management of UTUC and to incorporate recommendations into clinical practice. OBJECTIVE: To provide a brief overview of the EAU guidelines on UTUC as an aid to clinicians. EVIDENCE ACQUISITION: The recommendations provided in the current guidelines are based on a thorough review of available UTUC guidelines and articles identified following a systematic search of Medline. Data on urothelial malignancies and UTUC were searched using these keywords: urinary tract cancer; urothelial carcinomas; upper urinary tract, carcinoma; renal pelvis; ureter; bladder cancer; chemotherapy; nephroureterectomy; adjuvant treatment; instillation; neoadjuvant treatment; recurrence; risk factors; and survival. References were weighted by a panel of experts. EVIDENCE SYNTHESIS: Due to the rarity of UTUC, there are insufficient data to provide strong recommendations (ie, grade A). However, the results of recent multicentre studies are now available, and there is a growing interest in UTUC. The 2009 TNM classification is recommended. Recommendations are given for diagnosis and risk stratification as well as radical and conservative treatment, and prognostic factors are discussed. A single postoperative dose of intravesical mitomycin after nephroureterectomy reduces the risk of bladder tumour recurrence. Recommendations are also provided for patient follow-up after different therapeutic strategies. CONCLUSIONS: These guidelines contain information on the management of individual patients according to a current standardised approach. Urologists should take into account the specific clinical characteristics of each patient when determining the optimal treatment regimen, based on the proposed risk stratification of these tumours. PATIENT SUMMARY: Urothelial carcinoma of the upper urinary tract is rare, but because 60% of these tumours are invasive at diagnosis, an appropriate diagnosis is most important. A number of known risk factors exist.

22 Guideline Robot-assisted radical cystectomy and urinary diversion: technical recommendations from the Pasadena Consensus Panel. 2015

Chan, Kevin G / Guru, Khurshid / Wiklund, Peter / Catto, James / Yuh, Bertram / Novara, Giacomo / Murphy, Declan G / Al-Tartir, Tareq / Collins, Justin W / Zhumkhawala, Ali / Wilson, Timothy G / Anonymous770818. ·City of Hope Cancer Center, Duarte, CA, USA. Electronic address: kchan@coh.org. · Roswell Park Cancer Institute, Buffalo, NY, USA. · Karolinska Institute, Stockholm, Sweden. · University of Sheffield, Sheffield, UK. · City of Hope Cancer Center, Duarte, CA, USA. · University of Padua, Padua, Italy. · Peter MacCallum Cancer Centre, Melbourne, Australia. ·Eur Urol · Pubmed #25595099.

ABSTRACT: BACKGROUND: The technique of robot-assisted radical cystectomy (RARC) has evolved significantly since its inception >10 yr ago. Several high-volume centers have reported standardized techniques with refinements and subsequent outcomes. OBJECTIVE: To review all existing literature on RARC and urinary diversion techniques and summarize key points that may affect oncologic, surgical, and functional outcomes. DESIGN, SETTING, AND PARTICIPANTS: The Pasadena Consensus Panel on RARC and urinary reconstruction convened May 3-4, 2014, to review the existing peer-reviewed literature and create recommendations for best practice. The panel consisted of experts in open radical cystectomy and RARC. No commercial support was received. SURGICAL PROCEDURE: The consensus panel extensively reviewed the surgical technique of RARC in men and women, extended pelvic lymph node dissection, extracorporeal urinary diversion, and intracorporeal urinary diversion. Critical aspects of the technique are described. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Preoperative, operative, and postoperative parameters from the largest and most contemporary RARC series, stratified by urinary diversion technique, are presented. RESULTS AND LIMITATIONS: Preoperative, operative, and postoperative measures of RARC technique adhere closely to the standards established in open surgery. CONCLUSIONS: Refinement of techniques for RARC and urinary diversion over the past 10 yr has made it safe, reproducible, and oncologically sound. PATIENT SUMMARY: We summarize the critical aspects of surgical techniques reviewed at the Pasadena international consensus meeting on RARC and urinary reconstruction. Preoperative, operative, and postoperative measures of RARC technique adhere closely to the standards established in open surgery.

23 Guideline Best practices in robot-assisted radical cystectomy and urinary reconstruction: recommendations of the Pasadena Consensus Panel. 2015

Wilson, Timothy G / Guru, Khurshid / Rosen, Raymond C / Wiklund, Peter / Annerstedt, Magnus / Bochner, Bernard H / Chan, Kevin G / Montorsi, Francesco / Mottrie, Alexandre / Murphy, Declan / Novara, Giacomo / Peabody, James O / Palou Redorta, Joan / Skinner, Eila C / Thalmann, George / Stenzl, Arnulf / Yuh, Bertram / Catto, James / Anonymous4060817. ·City of Hope Cancer Center, Duarte, CA, USA. Electronic address: twilson@coh.org. · Roswell Park Cancer Institute, Buffalo, NY, USA. · New England Research Institutes, Inc., Watertown, MA, USA. · Karolinska Institutet, Stockholm, Sweden. · Urology STHLM, Stockholm, Sweden. · Memorial Sloan-Kettering Cancer Center, New York, NY, USA. · City of Hope Cancer Center, Duarte, CA, USA. · University Vita-Salute San Raffaele, Milan, Italy. · O.L.V. Clinic, Aalst, Belgium. · Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia. · University of Padua, Padua, Italy. · Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI, USA. · Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain. · Stanford University, Stanford, CA, USA. · University of Bern, Bern, Switzerland. · Eberhard Karls University of Tübingen, Tubingen, Germany. · University of Sheffield, Sheffield, UK. ·Eur Urol · Pubmed #25582930.

ABSTRACT: CONTEXT: Robot-assisted surgery is increasingly used for radical cystectomy (RC) and urinary reconstruction. Sufficient data have accumulated to allow evidence-based consensus on key issues such as perioperative management, comparative effectiveness on surgical complications, and oncologic short- to midterm outcomes. OBJECTIVE: A 2-d conference of experts on RC and urinary reconstruction was organized in Pasadena, California, and the City of Hope Cancer Center in Duarte, California, to systematically review existing peer-reviewed literature on robot-assisted RC (RARC), extended lymphadenectomy, and urinary reconstruction. No commercial support was obtained for the conference. EVIDENCE ACQUISITION: A systematic review of the literature was performed in agreement with the PRISMA statement. EVIDENCE SYNTHESIS: Systematic literature reviews and individual presentations were discussed, and consensus on all key issues was obtained. Most operative, intermediate-term oncologic, functional, and complication outcomes are similar between open RC (ORC) and RARC. RARC consistently results in less blood loss and a reduced need for transfusion during surgery. RARC generally requires longer operative time than ORC, particularly with intracorporeal reconstruction. Robotic assistance provides ergonomic value for surgeons. Surgeon experience and institutional volume strongly predict favorable outcomes for either open or robotic techniques. CONCLUSIONS: RARC appears to be similar to ORC in terms of operative, pathologic, intermediate-term oncologic, complication, and most functional outcomes. RARC consistently results in less blood loss and a reduced need for transfusion during surgery. RARC can be more expensive than ORC, although high procedural volume may attenuate this difference. PATIENT SUMMARY: Robot-assisted radical cystectomy (RARC) is an alternative to open surgery for patients with bladder cancer who require removal of their bladder and reconstruction of their urinary tract. RARC appears to be similar to open surgery for most important outcomes such as the rate of complications and intermediate-term cancer-specific survival. Although RARC has some ergonomic advantages for surgeons and may result in less blood loss during surgery, it is more time consuming and may be more expensive than open surgery.

24 Guideline Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer. 2015

Amin, Mahul B / Smith, Steven C / Reuter, Victor E / Epstein, Jonathan I / Grignon, David J / Hansel, Donna E / Lin, Oscar / McKenney, Jesse K / Montironi, Rodolfo / Paner, Gladell P / Al-Ahmadie, Hikmat A / Algaba, Ferran / Ali, Syed / Alvarado-Cabrero, Isabel / Bubendorf, Lukas / Cheng, Liang / Cheville, John C / Kristiansen, Glen / Cote, Richard J / Delahunt, Brett / Eble, John N / Genega, Elizabeth M / Gulmann, Christian / Hartmann, Arndt / Langner, Cord / Lopez-Beltran, Antonio / Magi-Galluzzi, Cristina / Merce, Jorda / Netto, George J / Oliva, Esther / Rao, Priya / Ro, Jae Y / Srigley, John R / Tickoo, Satish K / Tsuzuki, Toyonori / Umar, Saleem A / Van der Kwast, Theo / Young, Robert H / Soloway, Mark S. ·Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA. · Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. · Department of Pathology, Johns Hopkins Hospital, Baltimore, MD, USA. · Department of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA. · Department of Pathology, University of California San Diego, San Diego, CA, USA. · Department of Pathology, Cleveland Clinic Foundation, Cleveland, OH, USA. · Section of Pathological Anatomy, Polytechnic University of Medicine, United Hospitals, Ancona, Italy. · Department of Pathology, University of Chicago, Chicago, IL, USA. · Pathology Section, Fundacio Puigvert, Universitat Autónoma de Barcelona, Barcelona, Spain. · Department of Pathology, Mexican Oncology Hospital, Mexico City, Mexico. · Institute of Pathology, University Hospital Basel, Basel, Switzerland. · Division of Anatomic Pathology, Mayo Clinic, Rochester, MN, USA. · Institute of Pathology, University Hospital Bonn, Bonn, Germany. · Department of Pathology, University of Miami Miller School of Medicine, Miami, FL, USA. · Department of Pathology, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand. · Department of Pathology and Laboratory Medicine, Tufts Medical Center, Boston, MA, USA. · Department of Pathology, Beaumont Hospital, Dublin, Ireland. · Institute of Pathology, University Erlangen-Nürnberg, Erlangen, Germany. · Institute of Pathology, Medical University Graz, Graz, Austria. · Unit of Anatomical Pathology, Cordoba University Medical School, Faculty of Medicine, Cordoba, Spain. · James Homer Wright Pathology Laboratories, Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. · Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA. · Department of Pathology and Genomic Medicine, The Methodist Hospital Physician Organization, Weill Cornell Medical College of Cornell University, Houston, TX, USA. · Department Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada. · Department of Pathology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan. · Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA. ·Mod Pathol · Pubmed #25412849.

ABSTRACT: The International Consultations on Urological Diseases are international consensus meetings, supported by the World Health Organization and the Union Internationale Contre le Cancer, which have occurred since 1981. Each consultation has the goal of convening experts to review data and provide evidence-based recommendations to improve practice. In 2012, the selected subject was bladder cancer, a disease which remains a major public health problem with little improvement in many years. The proceedings of the 2nd International Consultation on Bladder Cancer, which included a 'Pathology of Bladder Cancer Work Group,' have recently been published; herein, we provide a summary of developments and consensus relevant to the practicing pathologist. Although the published proceedings have tackled a comprehensive set of issues regarding the pathology of bladder cancer, this update summarizes the recommendations regarding selected issues for the practicing pathologist. These include guidelines for classification and grading of urothelial neoplasia, with particular emphasis on the approach to inverted lesions, the handling of incipient papillary lesions frequently seen during surveillance of bladder cancer patients, descriptions of newer variants, and terminology for urine cytology reporting.

25 Guideline Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. 2014

Bellmunt, J / Orsola, A / Leow, J J / Wiegel, T / De Santis, M / Horwich, A / Anonymous4690802. ·Department of Medical Oncology, University Hospital del Mar-IMIM, Barcelona, Spain Bladder Cancer Center, Dana-Farber Cancer Institute/Brigham and Women's Cancer Center, Boston, USA. · Department of Urology, Vall d'Hebron University Hospital, Barcelona, Spain. · Department of Radio Oncology, University Hospital Ulm, Ulm, Germany. · Ludwig Boltzmann Institute for Applied Cancer Research, Kaiser Franz Josef- Spital, Vienna, Austria. · Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK. ·Ann Oncol · Pubmed #25096609.

ABSTRACT: -- No abstract --

Next